KT-531

Description	KT-531 is a potent, selective HDAC6 inhibitor with IC50 of 8.5 nM, displays 39-fold selectivity over other HDAC isoforms;KT-531 demonstrated biological potency in multiple hematological cancer cell models (acute myeloid leukemia (AML), PTCL, and T-cell acute lymphoblastic leukemia (T-ALL)) and limited cytotoxicity in nonmalignant cell types as well as no observable toxicity in vivo (CD-1 mice).KT-531 exhibited strong potency (IC50=0.42 μM) in the T-ALL/T-PLL-like cell line SUP-T11, demonstrated higher cytotoxicity than Nexturastat in MV4-11 cancer cells (IC50=0.42 uM versus 1.68 uM).KT-531 showed high synergy with chemotherapeutic agents idasanutlin, bendamustine, and venetoclax in T-PLL patient samples.KT-531 is the first HDAC6 inhibitor to show efficacy in T-PLL patient samples.
Pathways	Cell Cycle/DNA Damage
Targets	HDAC

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.